Cost-effectiveness analysis of donafenib versus lenvatinib for first-line treatment of unresectable or metastatic hepatocellular carcinoma
Article in Expert Review of Pharmacoeconomics & Outcomes Research (May 2022)
The most recent citing publications are shown below. View all 8 publications that cite this research output on Dimensions.
Article in Expert Review of Pharmacoeconomics & Outcomes Research (May 2022)
Article in Sustainability (December 2019)
Article in Value in Health Regional Issues (October 2019)